Skip to main content
SpringerLink
Log in

Concise review of the management of hepatitis C

  • Original Article
  • Published:
Comprehensive Therapy

Abstract

Hepatitis C is the most common blood-borne infection in the US affecting at least 2.7 million Americans today. The majority of infected patients remain asymptomatic until the end-stages of the disease, making the infection difficult to identify, study, and treat.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cohen, John. The scientific challenge of hepatitis C. Science. 1999;285:26–30.

    Article  PubMed  CAS  Google Scholar 

  2. Center for Disease Control and Prevention. Recommendations for prevention and control of HCV infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep. 1998;47 (RR-19):1–39.

    Google Scholar 

  3. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31:777–782.

    Article  PubMed  CAS  Google Scholar 

  4. Atler MJ, Kruszon-Moran D, Vainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;31:556–562.

    Google Scholar 

  5. Atler MJ. Epidemiology of hepatitis C in the West. Sem Liver Dis. 1995;15:5–14.

    Google Scholar 

  6. Gross JB. Clinician's guide to hepatitis C. Mayo Clin Proc. 1998;73:355–361.

    Article  PubMed  Google Scholar 

  7. Liang TJ (moderator), Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intenn Med. 2000;132:296–305.

    CAS  Google Scholar 

  8. Poynard T, Bedossa P, Okpolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997;349:825–832.

    Article  PubMed  CAS  Google Scholar 

  9. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112: 463–472.

    Article  PubMed  CAS  Google Scholar 

  10. The National Institute of Health Consensus Development Conference: Management of hepatitis C. Hepatology. 1997; 26:2S-10S.

    Article  Google Scholar 

  11. Catalina G, Navarro VJ. Hepatitis C: a challenge for the genralist. Hosp Prac. 2000;Jan 15:97–118.

    Article  Google Scholar 

  12. Carithers RL, Marquardt A, Gretch DR. Diagnostic testing for hepatitis C. Sem Liver Dis. 2000;20:159–171.

    Article  CAS  Google Scholar 

  13. Davis GL. Ourrent therapy for chronic hepatitis C. Gastroenterology 2000;118:S104-S114.

    Article  PubMed  CAS  Google Scholar 

  14. Trepo C, Linsay K, Neiderau C, et al. Pegylated interferon alfa-2b monotherapy is superior to interferon alfa-2b for the treatment of hepatitis C [Abstract G2S.07]. J Hepatol. 2000;32 (Suppl):29.

    Article  Google Scholar 

  15. Zeuzem S, Feinman SV, Rasenack J, et al. Evaluation and safety of once-weekly peg/interferon alfa-2a for chronic hepatitis C. A multinational randomized study [Abstract G2S. 08]. J Hepatol. 2000;32(Suppl):29.

    Article  Google Scholar 

  16. Hutchinson JG, Gordon SC, Schiff ER, et al. Interfereon alfa-2b alone or in combinatin with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1458–1492.

    Google Scholar 

  17. Poynard T, Marcellin P, Lee S, et al. Randomized trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet. 1998;352: 1426–1432.

    Article  PubMed  CAS  Google Scholar 

  18. Poynard T, McHutchison J, Goodman Z, Ling M, Albrecht J for the ALGORIRC Project Group. Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology. 2000;31:211–218.

    Article  PubMed  CAS  Google Scholar 

  19. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 1998;339:1493–1499.

    Article  PubMed  CAS  Google Scholar 

  20. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment naïve patients. Sem Liver Dis. 1999;19:67–76.

    CAS  Google Scholar 

  21. Schering Corporation Pharmaceuticals. Rebetron (Ribavirin & Recombinant Interferon Alfa-2b) Package Insert. Kenilworth, NJ: 1998.

  22. Linsay KL. Therapy of hepatitis C: overview. Hepatology. 1997;26:71S-77S.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Digestive Diseases Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street, P.O. Box 208019, 06520-8019, New Haven, Conn, USA

    Jili A. Addesa MD

  2. Division of Digestive Diseases Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street, P.O. Box 208019, 06520-8019, New Haven, Conn, USA

    Victor J. Navarro MD (Assistant Professor of Medicine & Epidemiology)

Authors
  1. Jili A. Addesa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Victor J. Navarro MD
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Addesa, J.A., Navarro, V.J. Concise review of the management of hepatitis C. Compr Ther 27, 275–283 (2001). https://doi.org/10.1007/s12019-001-0025-1

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12019-001-0025-1

Keywords

Search

Navigation